89 related articles for article (PubMed ID: 20732753)
41. P53 deficiency-induced Smad1 upregulation suppresses tumorigenesis and causes chemoresistance in colorectal cancers.
Ruan X; Zuo Q; Jia H; Chau J; Lin J; Ao J; Xia X; Liu H; Habib SL; Fu C; Li B
J Mol Cell Biol; 2015 Apr; 7(2):105-18. PubMed ID: 25757624
[TBL] [Abstract][Full Text] [Related]
42. Association of MicroRNA-652 Expression with Radiation Response of Colorectal Cancer: A Study from Rectal Cancer Patients in a Swedish Trial of Preoperative Radiotherapy.
Pathak S; Meng WJ; Sriramulu S; Jothimani G; Jangamreddy JR; Banerjee A; Ganesan AT; Adell G; Zhang X; Sun-Zhang A; Zhang H; Sun XF
Curr Gene Ther; 2023; 23(5):356-367. PubMed ID: 37076469
[TBL] [Abstract][Full Text] [Related]
43. Analysis of histological therapeutic effect, apoptosis rate and p53 status after combined treatment with radiation, hyperthermia and 5-fluorouracil suppositories for advanced rectal cancers.
Sakakura C; Koide K; Ichikawa D; Wakasa T; Shirasu M; Kimura A; Taniguchi H; Hagiwara A; Yamaguchi T; Inazawa J; Abe T; Takahashi T; Otsuji E
Br J Cancer; 1998; 77(1):159-66. PubMed ID: 9459162
[TBL] [Abstract][Full Text] [Related]
44. TP53 genotype but not p53 immunohistochemical result predicts response to preoperative short-term radiotherapy in rectal cancer.
Kandioler D; Zwrtek R; Ludwig C; Janschek E; Ploner M; Hofbauer F; Kührer I; Kappel S; Wrba F; Horvath M; Karner J; Renner K; Bergmann M; Karner-Hanusch J; Pötter R; Jakesz R; Teleky B; Herbst F
Ann Surg; 2002 Apr; 235(4):493-8. PubMed ID: 11923604
[TBL] [Abstract][Full Text] [Related]
45. Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer.
Nicolas AM; Pesic M; Engel E; Ziegler PK; Diefenhardt M; Kennel KB; Buettner F; Conche C; Petrocelli V; Elwakeel E; Weigert A; Zinoveva A; Fleischmann M; Häupl B; Karakütük C; Bohnenberger H; Mosa MH; Kaderali L; Gaedcke J; Ghadimi M; Rödel F; Arkan MC; Oellerich T; Rödel C; Fokas E; Greten FR
Cancer Cell; 2022 Feb; 40(2):168-184.e13. PubMed ID: 35120600
[TBL] [Abstract][Full Text] [Related]
46. A positive feedback loop between ID3 and PPARγ via DNA damage repair regulates the efficacy of radiotherapy for rectal cancer.
Huang C; Wang L; Chen H; Fu W; Shao L; Zhou D; Wu J; Ye Y
BMC Cancer; 2023 May; 23(1):429. PubMed ID: 37170184
[TBL] [Abstract][Full Text] [Related]
47. Targeting Acid Ceramidase to Improve the Radiosensitivity of Rectal Cancer.
Clifford RE; Govindarajah N; Bowden D; Sutton P; Glenn M; Darvish-Damavandi M; Buczacki S; McDermott U; Szulc Z; Ogretmen B; Parsons JL; Vimalachandran D
Cells; 2020 Dec; 9(12):. PubMed ID: 33334013
[TBL] [Abstract][Full Text] [Related]
48. Human phosphatidylethanolamine-binding protein 4 promoted the radioresistance of human rectal cancer by activating Akt in an ROS-dependent way.
Qiu J; Yang G; Lin A; Shen Z; Wang D; Ding L
PLoS One; 2014; 9(3):e90062. PubMed ID: 24594691
[TBL] [Abstract][Full Text] [Related]
49. P53 abnormalities and outcomes in colorectal cancer: a systematic review.
Munro AJ; Lain S; Lane DP
Br J Cancer; 2005 Feb; 92(3):434-44. PubMed ID: 15668707
[TBL] [Abstract][Full Text] [Related]
50. APR-246 Enhances Colorectal Cancer Sensitivity to Radiotherapy.
Xie X; Fan C; Luo B; Zhang J; Jensen LD; Burman J; Jönsson C; Ljusberg A; Larsson P; Zhao Z; Sun XF
Mol Cancer Ther; 2023 Aug; 22(8):947-961. PubMed ID: 37216282
[TBL] [Abstract][Full Text] [Related]
51. Paf15 expression correlates with rectal cancer prognosis, cell proliferation and radiation response.
Yan R; Zhu K; Dang C; Lan K; Wang H; Yuan D; Chen W; Meltzer SJ; Li K
Oncotarget; 2016 Jun; 7(25):38750-38761. PubMed ID: 27246972
[TBL] [Abstract][Full Text] [Related]
52. Expression of C-Reactive Protein in Rectal Cancer.
Contu PC; Contu SS; Rosito MA; Moreira LF
Gastroenterology Res; 2009 Apr; 2(2):104-109. PubMed ID: 27956962
[TBL] [Abstract][Full Text] [Related]
53. Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1.
Xu H; Zhao H; Ding C; Jiang D; Zhao Z; Li Y; Ding X; Gao J; Zhou H; Luo C; Chen G; Zhang A; Xu Y; Zhang H
Signal Transduct Target Ther; 2023 Feb; 8(1):51. PubMed ID: 36732502
[TBL] [Abstract][Full Text] [Related]
54. The beginning of GPX2 and 30 years later.
Esworthy RS; Doroshow JH; Chu FF
Free Radic Biol Med; 2022 Aug; 188():419-433. PubMed ID: 35803440
[TBL] [Abstract][Full Text] [Related]
55. The Cytotoxic Effect of Copper (II) Complexes with Halogenated 1,3-Disubstituted Arylthioureas on Cancer and Bacterial Cells.
Chrzanowska A; Drzewiecka-Antonik A; Dobrzyńska K; Stefańska J; Pietrzyk P; Struga M; Bielenica A
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768844
[TBL] [Abstract][Full Text] [Related]
56. Peroxiredoxins in Colorectal Cancer: Predictive Biomarkers of Radiation Response and Therapeutic Targets to Increase Radiation Sensitivity?
Fischer J; Eglinton TW; Frizelle FA; Hampton MB
Antioxidants (Basel); 2018 Oct; 7(10):. PubMed ID: 30301137
[TBL] [Abstract][Full Text] [Related]
57. The prognostic values of the peroxiredoxins family in ovarian cancer.
Li S; Hu X; Ye M; Zhu X
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30104402
[No Abstract] [Full Text] [Related]
58. Thioredoxin system-mediated regulation of mutant Kras associated pancreatic neoplasia and cancer.
Schultz MA; Diaz AM; Smite S; Lay AR; DeCant B; McKinney R; Mascarinas WE; Xia Y; Neumann C; Bentrem D; Dawson DW; Grippo PJ
Oncotarget; 2017 Nov; 8(54):92667-92681. PubMed ID: 29190947
[TBL] [Abstract][Full Text] [Related]
59. Identification of protein clusters predictive of tumor response in rectal cancer patients receiving neoadjuvant chemo-radiotherapy.
Repetto O; De Re V; De Paoli A; Belluco C; Alessandrini L; Canzonieri V; Cannizzaro R
Oncotarget; 2017 Apr; 8(17):28328-28341. PubMed ID: 28423701
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
